Press Releases

 

All Releases | Reset Search
Acquisitions | Business/Product | Corporate | Financial

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
05/01/15 Hospira Statement On FDA's Final Biosimilar Guidance DocumentsPrinter Friendly Version
04/28/15Hospira Reports First-Quarter 2015 ResultsPrinter Friendly Version
04/24/15Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on ExtrapolationPrinter Friendly Version
04/13/15Hope for Greater Access for Patients to Biosimilar MedicinesPrinter Friendly Version
04/07/15Hospira to Announce First-Quarter 2015 Results on April 28, 2015Printer Friendly Version
03/30/15Hospira's INFLECTRA™ (Infliximab) Now Available in CanadaPrinter Friendly Version
03/30/15Inflectra™ (Infliximab) De Hospira Est Désormais Printer Friendly Version
03/27/15Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's EpogenPrinter Friendly Version
03/06/15Hospira Statement on FDA Approval of the First Biosimilar in the United StatesPrinter Friendly Version
02/19/15Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory bowel diseasePrinter Friendly Version
02/16/15Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European marketsPrinter Friendly Version
02/12/15Hospira Reports Fourth-Quarter and Full-Year 2014 ResultsPrinter Friendly Version
02/10/15Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® BiosimilarPrinter Friendly Version
02/09/15Hospira Cancels Previously Scheduled Conference Call to Discuss Fourth-Quarter and Full-Year 2014 ResultsPrinter Friendly Version
02/05/15Pfizer To Acquire Hospira Printer Friendly Version
01/29/15Hospira to Host Conference Call for Fourth-Quarter 2014 Results and 2015 ProjectionsPrinter Friendly Version
01/20/15Hospira Receives FDA Clearance for Plum 360™ Infusion SystemPrinter Friendly Version
01/12/15Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa BiosimilarPrinter Friendly Version
01/11/15Hospira Statement On FDA Advisory Committee's Recommendation To Approve The First U.S. BiosimilarPrinter Friendly Version
01/08/15Hospira Announces Significant Progess On Global Device StrategyPrinter Friendly Version